Maximum Results with Dual GLP-1 + GIP Action
Compounded tirzepatide with B₁₂, featuring a revolutionary dual-agonist mechanism targeting both GLP-1 and GIP receptors. The most advanced weight loss medication available, prepared by a US-licensed pharmacy.
Tirzepatide is the first medication to harness both GLP-1 and GIP hormones for superior weight loss
Reduces appetite and hunger signals in the brain, slows gastric emptying for prolonged satiety, and enhances glucose-dependent insulin secretion.
Amplifies weight loss beyond GLP-1 alone, improves fat tissue metabolism and insulin sensitivity, and may reduce GI side effects through synergistic action.
The combination of both pathways creates a comprehensive approach that delivers superior results compared to single-agonist medications.
A GLP-1 receptor agonist that targets three key pathways to support sustainable weight loss
Feature
Tirzepatide
Semaglutide
Mechanism
Dual GLP-1/GIP
GLP-1 Only
Administration
Weekly
Weekly
Formulation
Compounded
Compounded
Starting Price
$249/mo
$147/mo
Best For
Maximum Weight Loss
Value + Proven Results
Dual-Action Formula
Targets both GLP-1 and GIP receptors for a comprehensive, synergistic approach to weight management.
Superior Weight Loss
Clinical trials show up to 22.5% average weight loss — significantly more than single-agonist options.
Appetite Management
May help reduce hunger and food-related thoughts more effectively through dual hormone pathways.
Metabolic Support
May support insulin sensitivity and blood sugar management through complementary mechanisms.
Body Composition
GIP activation may support metabolic processes that help preserve lean mass during weight loss.
Provider-Guided Protocol
Your provider will customize dosing and monitor progress throughout treatment for optimal results.
Your dose increases every 4 weeks over 20+ weeks to optimize results while minimizing side effects
1
2.5mg weekly
Starting dose — body begins adapting to the medication
5
5mg weekly
First therapeutic dose — noticeable appetite reduction
9
7.5mg weekly
Increased efficacy — weight loss accelerates
13
10mg weekly
Strong therapeutic effect — significant results visible
17
12.5mg weekly
Higher dose for enhanced response if needed
21
15mg weekly
Maximum dose — peak efficacy for weight loss
Compounded Tirzepatide is a customized medication prepared by a state-licensed sterile compounding pharmacy pursuant to a prescription from a licensed healthcare provider. Tirzepatide-based therapies are designed to support metabolic and weight management pathways through activity associated with GLP-1 and GIP receptors.
Compounded medications are not FDA-approved, which means the FDA does not evaluate them for safety, effectiveness, or quality before they are dispensed.
Individual results vary significantly based on factors like starting weight, diet, exercise, adherence to treatment, and individual physiology. In the SURMOUNT-1 trial, 36% of participants lost 25% or more of their body weight. Your provider will set realistic expectations during your consultation.
The dual mechanism works through complementary pathways: GLP-1 may help reduce appetite and slow gastric emptying. GIP may add metabolic benefits. Together, these pathways offer a comprehensive approach. Your provider will explain how this may apply to your specific health situation.
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite. These are typically mild-to-moderate and may diminish as your body adjusts. The gradual dose escalation protocol helps minimize these effects.
Tirzepatide commands a premium price due to its newer patent status and more complex dual-agonist formulation. It targets both GLP-1 and GIP receptors, offering a comprehensive approach. For patients seeking a dual-action option, Tirzepatide may be worth the investment.
Yes, many patients successfully switch from Semaglutide to Tirzepatide, especially if they've plateaued or want enhanced results. The switch should be done under medical supervision. Typically, you would stop Semaglutide and start Tirzepatide at a low dose, following the standard titration schedule.
